Mendoza, Rachelle P et al. “Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization.” Cancer medicine, 10.1002/cam4.6873. 2 Jan. 2024, doi:10.1002/cam4.6873
结论 In this study, we proposed a model-driven multi-modal deep learning model for the automated prediction of TP53 mutation in pancreatic cancer based on a small amount of data. A spiral transformation method was developed to apply 3D information with less computational resources and effectively a...
因此,认识肺腺癌中这一独特分子亚组具有预后和治疗意义。 参考文献:Mendoza, Rachelle P et al. “Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization.” Cancer medicine, 10.1002/cam4.6873. 2 Jan. 2024, doi:10.1002/cam4.6873...
^Sanchez-Lorenzo L, Sancho L, Iscar T, Grisham R, Chiva L. Management challenges in low-grade serous ovarian cancer with a BRCA mutation. Int J Gynecol Cancer. 2024 Apr 1;34(4):631-636. doi: 10.1136/ijgc-2023-005240. PMID: 38561200....
3. Zenz, T., Kreuz, M., Fuge, M., Klapper, W., Horn, H., Staiger, A.M., Winter, D., Helfrich, H., Huellein, J., Hansmann, M.L., et al. (2017). TP53 mutation and survival in aggressive B cell ...
体细胞突变(somatic mutation):大部分肿瘤细胞发生的是体细胞突变,突变局限于病变组织或系统中,不会遗传给子女,例如发生在造血系统的体细胞突变,在其它系统中不会被检出。体细胞突变比例一般<50%,但若伴随等位基因缺失(如伴随17p-),则突变比例>50%。
3. Zenz, T., Kreuz, M., Fuge, M., Klapper, W., Horn, H., Staiger, A.M., Winter, D., Helfrich, H., Huellein, J., Hansmann, M.L., et al. (2017). TP53 mutation and survival in aggressive B cell ...
因此,认识肺腺癌中这一独特分子亚组具有预后和治疗意义。 参考文献: Mendoza, Rachelle P et al. “Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization.” Cancer medicine, 10.1002/cam4.6873. 2 Jan. 2024, doi:10.1002/cam4.6873...
“Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.” Clinical cancer research : an official journal of the American Association for Cancer Research vol. 29,23 (2023): 4844-4852. doi:10.1158/1078-0432.CCR-23-...
[10]Graziano F, Fischer NW, Bagaloni I, et al. TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. Cancers (Basel). 2020;12(8):E2049. Publis...